Vaccines

Non-Needle Delivery

INCELL is developing non-needle delivery vaccines. Product development includes a variety of technologies and extensive collaborative research with INCELL’s capabilities in:

Innovative Technologies for PLATFORM Delivery: Oral, Nasal, other
New PLATFORM Modules: Cells, Vectors, antibodies, etc.
Stabilization PLATFORM Technologies to break the cold chain
PLATFORM cryostorage and banking capabilities

INCELL is working with many types of pathogens with its corporate, government, and academic partners.

INCELL’s oral and nasal smallpox vaccines, Oravax™-PX and NazVax™-PX, are providing a platform and foundation for INCELL’s other non-needle pipeline vaccines, such as those in development for human immunodeficiency virus (HIV; in collaboration with a large, international vaccines manufacturer), influenzas (including potential pandemic strains), and several category A-C biological threat agents, including Brucella and Coxiella (being developed with NIH and DoD support).

Pathogens in on-going studies include:
Smallpox, HIV, Salmonella, Influenza, Brucella, Coxiella, human herpesvirus 8, (HHV-8), staphylococcus, others

Animal and pre-clinical testing are part of on-going studies
Clinical testing is planned with DoD for Phase I Smallpox Vaccine testing
Vaccine features give INCELL’s vaccines a competitive edge

For Larger Image Click Here

INCELL and its partners are doing testing to assure that the vaccines are safe and effective. As examples, INCELL’s oral and nasal smallpox vaccines provide 100% protection and can safely be used even in immunodeficient animals.

These multiple features give INCELL’s oral smallpox vaccine a competitive edge.

For Larger Image Click Here